Show simple item record

Updates on radiotherapy-immunotherapy combinations: Proceedings of 6th annual ImmunoRad conference.

dc.contributor.authorGregucci, F
dc.contributor.authorSpada, S
dc.contributor.authorBarcellos-Hoff, MH
dc.contributor.authorBhardwaj, N
dc.contributor.authorChan Wah Hak, C
dc.contributor.authorFiorentino, A
dc.contributor.authorGuha, C
dc.contributor.authorGuzman, ML
dc.contributor.authorHarrington, K
dc.contributor.authorHerrera, FG
dc.contributor.authorHoneychurch, J
dc.contributor.authorHong, T
dc.contributor.authorIturri, L
dc.contributor.authorJaffee, E
dc.contributor.authorKaram, SD
dc.contributor.authorKnott, SRV
dc.contributor.authorKoumenis, C
dc.contributor.authorLyden, D
dc.contributor.authorMarciscano, AE
dc.contributor.authorMelcher, A
dc.contributor.authorMondini, M
dc.contributor.authorMondino, A
dc.contributor.authorMorris, ZS
dc.contributor.authorPitroda, S
dc.contributor.authorQuezada, SA
dc.contributor.authorSantambrogio, L
dc.contributor.authorShiao, S
dc.contributor.authorStagg, J
dc.contributor.authorTelarovic, I
dc.contributor.authorTimmerman, R
dc.contributor.authorVozenin, M-C
dc.contributor.authorWeichselbaum, R
dc.contributor.authorWelsh, J
dc.contributor.authorWilkins, A
dc.contributor.authorXu, C
dc.contributor.authorZappasodi, R
dc.contributor.authorZou, W
dc.contributor.authorBobard, A
dc.contributor.authorDemaria, S
dc.contributor.authorGalluzzi, L
dc.contributor.authorDeutsch, E
dc.contributor.authorFormenti, SC
dc.coverage.spatialUnited States
dc.date.accessioned2023-09-19T14:08:07Z
dc.date.available2023-09-19T14:08:07Z
dc.date.issued2023-12-31
dc.identifierARTN 2222560
dc.identifier2222560
dc.identifier.citationOncoImmunology, 2023, 12 (1), pp. 2222560 -en_US
dc.identifier.issn2162-4011
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/5978
dc.identifier.eissn2162-402X
dc.identifier.eissn2162-402X
dc.identifier.doi10.1080/2162402X.2023.2222560
dc.description.abstractFocal radiation therapy (RT) has attracted considerable attention as a combinatorial partner for immunotherapy (IT), largely reflecting a well-defined, predictable safety profile and at least some potential for immunostimulation. However, only a few RT-IT combinations have been tested successfully in patients with cancer, highlighting the urgent need for an improved understanding of the interaction between RT and IT in both preclinical and clinical scenarios. Every year since 2016, ImmunoRad gathers experts working at the interface between RT and IT to provide a forum for education and discussion, with the ultimate goal of fostering progress in the field at both preclinical and clinical levels. Here, we summarize the key concepts and findings presented at the Sixth Annual ImmunoRad conference.
dc.formatElectronic-eCollection
dc.format.extent2222560 -
dc.languageeng
dc.language.isoengen_US
dc.publisherTAYLOR & FRANCIS INCen_US
dc.relation.ispartofOncoImmunology
dc.rights.urihttps://creativecommons.org/licenses/by-nc/4.0en_US
dc.subjectFLASH radiotherapy
dc.subjectdose and fractionation
dc.subjectimmune checkpoint inhibitors
dc.subjectimmunomodulators
dc.subjectlymph node sparing
dc.subjecttumor-associated macrophages
dc.subjectHumans
dc.subjectCombined Modality Therapy
dc.subjectNeoplasms
dc.subjectImmunotherapy
dc.titleUpdates on radiotherapy-immunotherapy combinations: Proceedings of 6th annual ImmunoRad conference.en_US
dc.typeJournal Article
dcterms.dateAccepted2023-06-02
dc.date.updated2023-09-19T13:59:41Z
rioxxterms.versionVoRen_US
rioxxterms.versionofrecord10.1080/2162402X.2023.2222560en_US
rioxxterms.licenseref.startdate2023-12-31
rioxxterms.typeJournal Article/Reviewen_US
pubs.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/37363104
pubs.issue1
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology/Targeted Therapy
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Targeted Therapy
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Translational Immunotherapy
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Translational Immunotherapy/Translational Immunotherapy (TL)
pubs.organisational-group/ICR/Students
pubs.organisational-group/ICR/Students/PhD and MPhil
pubs.organisational-group/ICR/ImmNet
pubs.organisational-group/ICR/Students/PhD and MPhil/21/22 Starting Cohort
pubs.organisational-group/ICR/Students/PhD and MPhil/13/14 Starting Cohort
pubs.publication-statusPublished online
pubs.publisher-urlhttp://dx.doi.org/10.1080/2162402x.2023.2222560
pubs.volume12
icr.researchteamTrans Immunotherapyen_US
icr.researchteamTargeted Therapyen_US
dc.contributor.icrauthorChan Wah Hak, Charleen Min Li
dc.contributor.icrauthorHarrington, Kevin
dc.contributor.icrauthorMelcher, Alan
dc.contributor.icrauthorCorbett, Anna
icr.provenanceDeposited by Dr Charleen Chan Wah Hak on 2023-09-19. Deposit type is initial. No. of files: 1. Files: Updates on radiotherapy-immunotherapy combinations Proceedings of 6supthsup annual ImmunoRad conference.pdf


Files in this item

Thumbnail
Name:
Updates on radiotherapy-immuno ...
Size:
490.9Kb
Format:
PDF
View/Open

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by-nc/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by-nc/4.0